Passage Bio

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Passage Bio, 1 Commerce Square, 39th Floor, Philadelphia, PA.

02/06/2026

Transforming lives is at the heart of our mission. This Patient Recognition Week, we honor and thank the patients who inspire our work every day and remind us that true success is measured by one thing: making a meaningful difference in their lives.

02/03/2026

Empowering families with information is an important part of our work. Learn how genetic testing and counseling can help guide informed decisions for people that might have frontotemporal dementia caused by a mutation in the GRN gene (FTD-GRN) by visiting our website: https://loom.ly/WlVc6rQ

01/19/2026

Today, we pause to reflect on Dr. King’s enduring message of compassion, courage, and service.

12/23/2025

Giving back to the community where we live and work is something we value at Passage Bio. Recently, our team spent time with Broad Street Love, supporting their mission to provide stabilizing services for those experiencing deep poverty. It was an inspiring day filled with teamwork and the chance to make a meaningful impact right here in Philadelphia.

12/09/2025

There is still time to register for tomorrow’s The Association for Frontotemporal Degeneration webinar reviewing key developments in FTD research. This session will offer valuable insights into the scientific advancements informing future therapeutic strategies.

We are proud to sponsor this event and support continued progress in the field: https://bit.ly/4rfNmOq

12/03/2025

We’re proud to support The Association for Frontotemporal Degeneration by sponsoring their upcoming webinar exploring FTD research and the path towards developing effective treatments. To join the discussion, visit: https://bit.ly/4rfNmOq

11/27/2025

This Thanksgiving, we’re thankful for our dedicated team and the patients and families who inspire our mission every day: https://loom.ly/k5OydyI

10/09/2025

Raising awareness starts with understanding. Watch our Myth vs. Fact video to separate fact from fiction about FTD.

09/25/2025

This , we honor families and caregivers navigating the challenges of FTD. Their resilience inspires us to keep supporting the community through research, collaboration, and learning.

09/22/2025

Frontotemporal degeneration (FTD) is one of the most common causes of early-onset dementia worldwide, yet it is often misunderstood and misdiagnosed. This World FTD Awareness Week, we join The Association for Frontotemporal Degeneration and the community to raise awareness, support families, and drive progress toward better care and treatments.

07/28/2025

We’re working to bring hope to people living with neurodegenerative diseases. Our investigational gene therapies use AAVs (adeno-associated viruses) to deliver working copies of genes directly to the central nervous system. This approach is designed to target the root cause of disease and may offer long-term benefits with a single targeted treatment.

Learn more: https://loom.ly/xNiGJvk

06/27/2025

Frontotemporal dementia is often mistaken for mental health conditions or Alzheimer’s disease, making awareness and accurate diagnosis crucial. Understanding the signs can help ensure timely support and care.

Address

1 Commerce Square, 39th Floor
Philadelphia, PA
19103

Website

https://www.passagebio.com/

Alerts

Be the first to know and let us send you an email when Passage Bio posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Passage Bio:

Shortcuts

Want your practice to be the top-listed Clinic in Philadelphia?

About Passage Bio

Passage Bio is a fully integrated genetic medicines company based in Philadelphia, PA that is developing a portfolio of five life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company was founded by industry veterans Stephen Squinto, Ph.D., and Tachi Yamada, M.D., in a partnership with gene therapy pioneer James Wilson, M.D., Ph.D.

The company has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program as well as the Penn Orphan Disease Center.